{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:24:08Z","timestamp":1791289448093,"version":"4.3.0"},"reference-count":41,"publisher":"Wiley","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiology Research and Practice"],"published-print":{"date-parts":[[2021,3,30]]},"abstract":"<jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent newly developed oral antidiabetic drugs that are practiced for type 2 diabetes mellitus management and may decrease the risk of the first hospitalization in heart failure. The activity of SGLT2 inhibitors is not related to glucose, and the effectiveness and safety of SGLT2 inhibitors in individuals with chronic heart failure (CHF) remain unclear. We systematically retrieved PubMed, Cochrane Library, Embase, NCKI, VIP, Wanfang Data, and ClinicalTrials.gov records to identify eligible trials. The primary endpoints were cardiovascular death\/hospitalization for heart failure (CV death\/HHF), cardiovascular death, and hospitalization for heart failure. Secondary endpoints included hypoglycemia, volume depletion, urinary tract infection, left ventricular ejection fraction (LVEF), and NT-proBNP. Nine randomized controlled clinical trials were included. Dapagliflozin was reported to significantly decrease CV death\/HHF (relative risk (RR): 0.75; 95% confidence interval (CI): 0.68\u20130.84), CV death (RR: 0.80; 95% CI: 0.68\u20130.93), and HHF (RR: 0.72; 95% CI: 0.63\u20130.83). There was no effect on hypoglycemia (RR: 0.69; 95% CI: 0.34\u20131.40), volume depletion (RR: 1.17; 95% CI: 0.97\u20131.41), urinary tract infection (RR: 0.82; 95% CI: 0.43\u20131.57), LVEF (WMD: 0.53; 95% CI: \u22124.04\u20135.09), or NT-proBNP (SMD: \u22120.66; 95% CI: \u22121.42\u20130.10). The risk of CV death\/HHF, CV death, and HHF was lower among patients receiving dapagliflozin than patients receiving placebo.<\/jats:p>","DOI":"10.1155\/2021\/6657380","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T21:35:08Z","timestamp":1617226508000},"page":"1-12","source":"Crossref","is-referenced-by-count":17,"title":["Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis"],"prefix":"10.1155","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5462-6365","authenticated-orcid":true,"given":"Ru-ping","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Guilin Medical University, Guilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-li","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Guilin Medical University, Guilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-7921","authenticated-orcid":true,"given":"Qiang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Affiliated Hospital of Guilin Medical University, Guilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"issue":"10100","key":"2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.116.023518"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.037778"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504720"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1811744"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611925"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812389"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32590-x"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042929"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.040130"},{"issue":"5","key":"13","first-page":"599","article-title":"Therapeutic effect of dapagliflozin on patients with diabetes mellitus complicated HF and its influence on vascular endothelial function and inflammatory factor levels","volume":"29","author":"J. Chen","year":"2020","journal-title":"Chinese Journal of Cardiovascular Rehabilitation Medicine"},{"issue":"11","key":"14","first-page":"1350","article-title":"Analysis of the effect of dapagliflozin on HbA1c level and heart function in patients with diabetes mellitus complicated with chronic heart failure","volume":"31","author":"Z. Chen","year":"2020","journal-title":"Journal of Aerospace Medicine"},{"issue":"18","key":"15","first-page":"2505","article-title":"Effects of Dapagliflozin on mid-range ejection fraction heart failure patients with type 2 diabetes","volume":"36","author":"R. Dai","year":"2020","journal-title":"The Journal of Practical Medicine"},{"issue":"4","key":"16","first-page":"124","article-title":"Clinical study of metformin combined with dapagliflozin in the treatment of type 2 diabetes patients with heart failure","volume":"17","author":"Li Meng","year":"2020","journal-title":"Journal of North Pharmacy"},{"key":"17","first-page":"1016","article-title":"Application of dapagliflozin in treatment of elderly CHF patients with type 2 DM and hyperuricemia","author":"X. Tong","year":"2020"},{"issue":"16","key":"18","first-page":"2861","article-title":"Clinical evaluation and analysis of dapagliflozin in patients with type 2 diabetes and cardiac insufficiency","volume":"48","author":"Z. Yang","year":"2019","journal-title":"Chongqing Medicine"},{"key":"19","article-title":"Chapter 8: assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"J. P. T. Higgins","year":"2011"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117090"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.044133"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1906"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.044138"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.1891"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-019-0920-4"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2017.08.005"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.116.005066"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.253666"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.029166"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2017.01.035"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.2275"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4670-7"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.035759"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.030012"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.09.005"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1515920"},{"key":"38"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc1701990"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12896"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365"}],"container-title":["Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/crp\/2021\/6657380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crp\/2021\/6657380.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crp\/2021\/6657380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T21:35:16Z","timestamp":1617226516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/crp\/2021\/6657380\/"}},"subtitle":[],"editor":[{"given":"Frank","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":41,"alternative-id":["6657380","6657380"],"URL":"https:\/\/doi.org\/10.1155\/2021\/6657380","relation":{},"ISSN":["2090-0597","2090-8016"],"issn-type":[{"value":"2090-0597","type":"electronic"},{"value":"2090-8016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}